From Nasdaq, Inc.: 2025-01-06 16:45:11

Stryker has announced its plans to acquire Inari Medical for $4.9 billion, with a deal price of $80 per share in cash. This move will allow Stryker to expand its portfolio and offer life-saving solutions in the peripheral vascular market, specifically in venous thromboembolism (VTE) treatment. The acquisition has been approved by both companies’ boards of directors and is expected to close by the end of the first quarter of 2025. This strategic decision will enhance Stryker’s impact in endovascular procedures and elevate the standard of care for VTE patients.



Read more at Nasdaq, Inc.: Stryker To Buy Inari Medical For About $4.9 Bln